Cancer Institute and Hospital, Chinese Academy of Medical Sciences
459
156
183
57
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.1%
5 terminated/withdrawn out of 459 trials
91.9%
+5.4% vs industry average
10%
46 trials in Phase 3/4
5%
3 of 57 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (459)
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy
Role: lead
A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy
Role: lead
Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma
Role: lead
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Role: lead
The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy
Role: lead
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Role: lead
A Retrospective Real-World Study Based on RATIONALE-307
Role: lead
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
Role: collaborator
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Role: lead
Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
Role: lead
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Role: lead
Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites
Role: lead
Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
Role: lead
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Role: lead
Omitting Nasogastric Tube Decompression in Minimally Invasive Pancreaticoduodenectomy
Role: lead
An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases
Role: lead
Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Role: lead
Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics
Role: lead
Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
Role: lead